Medpace Holdings, INC Form 4 insider transactions

August J. Troendle, President & CEO, a Director and 10% owner of Medpace Holdings, Inc., sold 23,144 shares of common stock on August 10, 2026.

Cornelius P. Mccarthy Iii, a Director of Medpace Holdings, Inc., sold 795 shares of common stock on August 7, 2026 for $585.07 per share.

August J. Troendle, President & CEO, a Director and 10% owner of Medpace Holdings, Inc., sold 7,238 shares of common stock on July 27, 2026.

Susan E Burwig, Exec. VP, Operations of Medpace Holdings, Inc., sold 7,500 shares of common stock on July 28, 2026 for $600.00 per share.

Robert O. Kraft, a Director at Medpace Holdings, Inc., has acquired 33 restricted stock units, converting them into common stock.

Stephen P. Ewald, General Counsel & Corp. Secy. of Medpace Holdings, Inc., reported transactions involving the acquisition and disposition of common stock.

Medpace Holdings, Inc. director Dani S. Zander was granted 1,110 stock options as part of standard board compensation.

Medpace Holdings, Inc. director Cornelius P. McCarthy III was granted 1,110 stock options as part of standard equity compensation.

Director Robert O. Kraft was granted 1,110 stock options in Medpace Holdings, Inc. as part of standard equity compensation.

Director Femida H. Gwadry-Sridhar was granted 1,110 stock options in Medpace Holdings, Inc. as part of standard equity compensation.

Fred B. Davenport Jr., a Director and 10% Owner of Medpace Holdings, Inc., acquired 1,110 stock options with an exercise price of $415.27, vesting based on service.

Medpace Holdings Director Brian T. Carley reports the acquisition of a stock option grant, with vesting contingent on continued service.

Medpace Holdings CEO August J. Troendle acquired 20,000 employee stock options and 10,000 restricted stock units, reflecting continued investment in the company.

Medpace Holdings Inc. reports insider transactions involving common stock, stock options, and restricted stock units by General Counsel & Corp. Secy. Stephen P. Ewald.

Medpace Holdings, Inc. reports that Executive Vice President Susan E. Burwig was granted stock options and restricted stock units.

Medpace Holdings CFO Kevin M. Brady reports significant transactions including the acquisition of common stock and the exercise of stock options.

Cornelius P. McCarthy III, a Director at Medpace Holdings, Inc., acquired 29 shares of common stock on March 31, 2026, through the vesting of restricted stock units.

Medpace Holdings Director Robert O. Kraft reported the acquisition of 33 shares of common stock on March 31, 2026, through restricted stock units.

Brian T. Carley, a Director at Medpace Holdings, Inc., acquired 36 shares of common stock through the vesting of restricted stock units.

Medpace Holdings' Executive VP of Operations, Susan E. Burwig, exercised 12,000 stock options and acquired common stock.

Medpace Holdings President Jesse J. Geiger exercised stock options and subsequently sold 31,707 shares of common stock under a pre-arranged plan.

Medpace Holdings Director Cornelius P. McCarthy III acquired 49 shares of common stock through the vesting of restricted stock units.

Medpace Holdings Director Robert O. Kraft converted 56 restricted stock units into common stock, increasing his direct ownership to 889 shares.

Medpace Holdings Director Brian T. Carley converted 62 restricted stock units into common stock on December 31, 2025, increasing his direct beneficial ownership to 26,281 shares.

Medpace Holdings, Inc. Executive Vice President of Operations, Susan E. Burwig, exercised 10,000 employee stock options at $107.93 per share.

Medpace Holdings, Inc. CEO August J. Troendle reported the sale of 668 shares of common stock at a weighted average price of $590.69.

Medpace Holdings Executive VP of Operations, Susan E. Burwig, exercised and sold 10,000 shares of common stock under a pre-arranged plan.

Medpace Holdings CEO August J. Troendle reported selling over $17 million worth of company common stock in early December 2025.

Medpace Holdings, Inc. Director Cornelius P. McCarthy III was granted 113 restricted stock units, vesting quarterly through December 2026.

Medpace Holdings, Inc. Director Robert O. Kraft received a grant of 130 restricted stock units, vesting quarterly throughout 2026.